摘要
目的研究分析脐血CIK细胞联合吉西他滨与卡铂治疗晚期非小细胞肺癌患者的临床效果。方法选取2013年2月至2014年2月本院收治的60例晚期非小细胞肺癌患者为研究对象，随机分成研究组（n=30，治疗方案：脐血CIK细胞＋吉西他滨＋卡铂）和对照组（n=30，治疗方案：吉西他滨＋卡铂）。比较两组临床有效率、不良反应发生情况以及生活质量变化情况。结果研究组和对照组有效率分别为66．67％、30．00％，差异有统计学意义（P〈0．05）；研究组肝肾功能损害、消化道反应等不良反应发生率均明显低于对照组（P〈0．05）；治疗后，两组生活质量均得到改善，且研究组生活质量评分更佳，P〈0．05。结论脐血CIK细胞联合吉西他滨与卡铂治疗晚期非小细胞肺癌患者具有理想的疗效，并且不良反应症状少，安全有效，患者生活质量得到明显提高，值得推广应用。
Objective To study the clinical effect of umbilical cord blood CIK cells in combination with gemcitabine and carboplatin for patients with advanced non-small cell lung cancer. Methods 60 patients with advanced non-small cell lung cancer admitted into our hospital from February, 2013 to February, 2014 were selected as study objects and were randomly divided into a study group （n=30, treated with umbilical cord blood CIK cells and gemcitabine ＋ carboplatin） and a control group （n=30, treated with gemcitabine ＋ carboplatin）. The clinical efficacies, the incidence of adverse reactions, and the changes quality of life were compared between these two groups. Results The effective rate was 66.67% in the study group and 30.00% in the control group, with a statistical difference （P〈0.05）. The incidences of liver and kidney dysfunction, gastrointestinal reactions, and other adverse reactions were significantly lower in the study group than in the control group （P〈0.05）. After the treatment, the quality of life was improved in both groups and was better in the study group than in the control group （P〈0.05）. Conclusions Cord blood CIK cells in combination with gemcitabine and carboplatin for patients with advanced non-small cell lung cancer is effective and safe, has few adverse symptoms, can significantly improve the patients＇ quality of life, so it is worth being generalized.
出处
《国际医药卫生导报》
2016年第10期1398-1401,共4页
International Medicine and Health Guidance News
关键词
脐血CIK细胞
吉西他滨
卡铂
晚期非小细细胞肺癌患者
Cord blood CIK cells
Gemcitabine
Carboplatin
Patients with advanced non-small celllung cancer
